Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019829 (
Hodgkin's disease
)
30,247
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The purpose of this study was to increase the sensitivity of the staining reaction for the T antigen on the surface of neoplastic cells grown in vitro with the use of site-specific monoclonal antibodies (MAbs). The authors describe anti-peanut agglutinin (PNA) MAbs selected by screening the hybridomas with PNA and PNA bound to bovine serum albumin conjugated with the T antigen. The selected hybridomas (F2C8, F3D12, F3A5) were then grown in pristane-sensitized mice or in the Amicon Hollow Fiber System (F2C8). The affinity constant values for PNA were measured, and all the purified MAbs were tested on both native and denatured PNA, wheat germ agglutinin, concanavalin A, and ricin by using the immunoassay dot test and immunoblotting methods. Eleven different cell lines were stained with the three MAbs; similar results were obtained with F2C8 and F3D12. In each case the fluorescence, if present, was associated with the cell membrane, and the intensity of the staining was always stronger when the cells were incubated with the MAbs than when stained with fluorescein-labeled PNA. On the other hand, F3A5 failed to stain unfixed cells preincubated with PNA but stained the same cells after fixation, independently of the presence of PNA. One of the antibodies, F2C8, was used to stain histologic preparations from 27 cases of
Hodgkin's disease
and was compared with the anti-
granulocyte
antibody, Leu-M1, which has been used by numerous authors to identify the characteristic Reed-Sternberg cells. The results obtained were qualitatively similar; ie, F2C8 was at least as efficient as anti-Leu-M1 in its ability to stain the typical diagnostic cells in
Hodgkin's disease
.
...
PMID:Site-specific monoclonal antibodies against peanut agglutinin (PNA) from Arachis hypogaea. Immunohistochemical study of tissue-cultured cells and of 27 cases of Hodgkin's disease. 328 47
The immunoreactivity of eight monoclonal antibodies was evaluated on 45 routinely processed lymphomas (22 T-cell lymphomas, 11 B-cell lymphomas, and 12 cases of
Hodgkin's disease
). Two antibodies reactive with leukocyte common (T200) antigens (PD7/26 and 2B11) stained most of the B- and T-cell lymphomas but did not stain the Reed-Sternberg cells and variants in
Hodgkin's disease
. Two antibodies known to stain B cells (LN-1 and LN-2) reacted with some of the B-cell lymphomas, but LN-2 also reacted with the neoplastic cells in six of 22 T-cell lymphomas and with the Reed-Sternberg variants in eight of 12 cases of
Hodgkin's disease
. The
granulocyte
antibody anti-Leu M1 reacted with most cases of
Hodgkin's disease
but also reacted with two of 11 B-cell non-
Hodgkin
's lymphomas. An antibody to epithelial membrane antigen (anti-EMA) stained some cases of T-cell lymphoma, B-cell lymphoma, and
Hodgkin's disease
. Leu 7 was expressed in one T-cell lymphoma and in one case of
Hodgkin's disease
. A novel antibody reactive with T cells (L60) stained all cases of T-cell lymphoma but also stained some cases of B-cell lymphoma and one case of
Hodgkin's disease
. We conclude that none of these antibodies, when used alone on routinely fixed paraffin-embedded material, is completely sensitive and specific for T-cell lymphoma, B-cell lymphoma, or
Hodgkin's disease
. However, a panel of antibodies is useful in distinguishing
Hodgkin's disease
from non-Hodgkin's lymphoma and in suggesting the B- or T-cell phenotype of non-
Hodgkin
's lymphomas.
...
PMID:Monoclonal antibodies reactive in routinely processed tissue sections of malignant lymphoma, with emphasis on T-cell lymphomas. 330 26
Zinc status and the effect of zinc supplementation were assessed in groups of patients with non-Hodgkin's lymphoma and
Hodgkin's disease
; patients were either untreated or in remission. In the patients in remission, plasma zinc was normal; and whereas 30% of untreated patients had low plasma zinc, the group as a whole did not differ from normal. For mononuclear cell zinc, the range of values in the disease group was far wider than in controls, but there was no significant difference between the means of the groups. Granulocyte zinc was significantly lower in both the groups of patients in remission from non-Hodgkin's lymphoma and
Hodgkin's disease
compared with the control group. Significant increases were found in the plasma copper, ceruloplasmin, and the copper-to-zinc ratio in several of the patient groups. Plasma zinc increased by 23% with zinc supplementation (50 mg elemental Zn/day), but there was no effect on mononuclear cell or
granulocyte
zinc. Apart from
granulocyte
zinc, there is little evidence of zinc deficiency in non-Hodgkin's lymphoma or
Hodgkin's disease
. However, the presence of depleted
granulocyte
zinc levels could modify the immune function of this cell population.
...
PMID:Leucocyte zinc in non-Hodgkin's lymphoma and Hodgkin's disease. 336 23
Doxorubicin is an anthracycline widely used in the treatment of leukaemias, lymphomas and solid tumors. Doxorubicin cannot pass into the cerebrospinal fluid. Nitrosoureas are known to be lipophilic and to be able to penetrate the blood-brain barrier. CCNU is a nitrosourea used to treat
Hodgkin's disease
, brain tumors and other solid tumors. The authors have previously reported on the nephrotoxicity and hepatotoxicity of these drugs; the present paper reports their findings on haematotoxicity in female Wistar rats. In one group 40 rats received 10 mg/kg doxorubicin. In a second group 40 rats received 20 mg/kg CCNU, and a further 40 rats received 50 mg/kg CCNU. In a third group 60 rats received the association doxorubicin 10 mg/kg plus CCNU 20 mg/kg. Blood counts were performed on days 4, 8, 15, 21 and 28 after treatment. Leucopenia and severe thrombocytopenia were noted after doxorubicin administration. A biphasic decrease in the leucocyte count was observed after CCNU treatment. More severe alterations were observed when doxorubicin and CCNU were combined. Very few data on haematological abnormalities following treatment of human patients have been published. Similarities can be seen between the haematological side-effects noted in rats and those occurring in humans treated with these cytotoxic drugs. Female Wistar rats seemed to be a good model to evaluate the haematological tolerance of anthracycline, nitrosoureas or of their association. If multiple courses of these drugs have to be administered, the evolution of haematological alterations must be known: the decrease phase of blood cells is followed by a rebound phase. The drug should be avoided during this phase of
granulocyte
activation.
...
PMID:Haematotoxicity of doxorubicin and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and of their association in rats. 342 23
A series of 50 specimens of
Hodgkin's disease
and 10 of reactive follicular hyperplasia were examined by means of indirect immunoperoxidase staining with a monoclonal antibody AGF 4.48: this is known to bind to 3-fucosyl-N-acetyllactosamine, which, in particular, is expressed by
granulocyte
series cells. Most Reed-Sternberg and many
Hodgkin
's cells were labelled by the antibody after pretreatment with neuraminidase. Routinely processed paraffin wax embedded sections proved suitable for staining. The findings were comparable with those reported by others with monoclonal antibodies to various other
granulocyte
markers. This technique is of potential diagnostic value.
...
PMID:Presence of 3-fucosyl-N-acetyllactosamine shown by monoclonal antibody AGF 4.48 in Reed-Sternberg cells. 352 34
To throw light on the question of whether B-cell-derived forms of
Hodgkin's disease
exist, more than 100 cases of
Hodgkin's disease
(including all four major histologic categories) were investigated for the presence of J chain and were also immunostained for epithelial membrane antigen and the
granulocyte
-associated antigen X hapten. Reed-Sternberg and
Hodgkin
cells (RS & H) expressed J chain in 22 cases, 8 of which also expressed epithelial membrane antigen (EMA). X hapten was found in 62 cases, but all of these were J chain negative. J chain-positive RS & H cells were restricted to cases of lymphocyte-predominant disease, while X hapten-positive tumor cells were found frequently in nodular sclerosis, mixed cellularity, and lymphocyte-depletion
Hodgkin's disease
, but only occasionally in cases of lymphocyte-predominant disease. These findings indicate that nodular lymphocyte-predominant
Hodgkin's disease
differs from the other subtypes of
Hodgkin's disease
and that the neoplastic cells are of B-lymphoid origin.
...
PMID:Reed-Sternberg and Hodgkin cells in lymphocyte-predominant Hodgkin's disease of nodular subtype contain J chain. 352 24
Formalin fixed and paraffin wax embedded tissue from 24 cases of T-cell lymphoma diagnosed using immunocytochemistry on cryostat sections was examined using a panel of eight monoclonal and three polyclonal antisera. The monoclonal antibodies UCHL1 and MT1 proved to be comparable and reliable markers of neoplastic cells in T-cell lymphomas. The B-cell specific marker, MB1, strongly stained all cells in two cases of pleomorphic large cell T-cell lymphoma, large cells in two cases of pleomorphic mixed medium and large cell lymphoma, and isolated clusters of blast cells in four cases of T-zone and angioimmunoblastic lymphadenopathy-like T-cell lymphoma. The cells stained by MB1 expressed T suppressor/cytotoxic surface markers on frozen section. Epithelial membrane antigen, as detected by a polyclonal anti-EMA and the monoclonal antibody HMFG2, was expressed in 36% of tumours especially those of monomorphic large cell and pleomorphic large cell phenotype. Single granules or finely dispersed cytoplasmic granularity was seen in four tumours using the anti-
granulocyte
reagent Leu M1. Tumour cells in one case stained in a pattern identical to Reed-Sternberg cells in
Hodgkin's disease
. Granular alpha-1-antitrypsin staining was found in 10 cases of pleomorphic large cell and monomorphic large cell lymphoma. No staining was observed using anti-lysozyme or the monoclonal macrophage specific marker Mac411. Monomorphic and pleomorphic large cell lymphomas tended to show a common immunophenotype with the majority of cells co-expressing alpha-1-antitrypsin HLA-DR and epithelial membrane antigen. Scattered large transformed blast cells in cases of angioimmunoblastic lymphadenopathy-like T-cell lymphomas and T-zone lymphomas shared a similar immunophenotype with the large cell lymphomas. Using a panel of monoclonal antibodies effective in paraffin embedded tissue, diagnostically useful staining profiles which correlate with the morphological phenotype can be established in T-cell lymphomas.
...
PMID:An immunocytochemical study of T-cell lymphomas using monoclonal and polyclonal antibodies effective in routinely fixed wax embedded tissues. 354 52
The immunoreactivity of six different monoclonal antigranulocyte antibodies (Leu M1, TG1, 3C4, BY/87a, BY/37a, and 3CD1) has been evaluated in 23 cases of
Hodgkin's disease
(7 lymphocyte predominant, 12 nodular sclerosing, and 5 mixed cellularity); in a variety of non-
Hodgkin
's lymphomas and in a series of reactive and benign lesions of lymph nodes. Applying a monoclonal antibody (PD7/26) to leukocyte common antigen (T200), we have also investigated reports that the L&H variants in nodular lymphocyte predominant
Hodgkin's disease
are strongly immunoreactive for leukocyte common antigen in contrast to the lack of reactivity of Reed-Sternberg (RS) cells and variants thereof in other forms of
Hodgkin's disease
. All six monoclonal anti-
granulocyte
antibodies reacted against RS cells and "Hodgkin's cells" in the nodular sclerosing (NSHD) and mixed cellularity (MCHD) types, with strong cell membrane and juxtanuclear (Golgi) staining. In contrast an anti-leukocyte antibody PD7/26 was unreactive with RS cells and variants thereof in NSHD and MCHD. On the other hand, RS cells and L&H variants thereof in the nodular L&H form of
Hodgkin's disease
(nodular lymphocyte predominant type) showed reactivity with PD7/26 but not with the anti-
granulocyte
markers. Rare L&H cells in 2 cases of diffuse lymphocyte predominant type showed reactivity with some, but not all, of the anti-
granulocyte
antibodies. These findings provide further support for the concept that the nodular L&H type of
Hodgkin's disease
represents an entity distinct from other forms of this disorder. Our studies also demonstrate the usefulness of these immunoperoxidase techniques when applied to formalinfixed, paraffin-embedded tissues.
...
PMID:An evaluation of the utility of anti-granulocyte and anti-leukocyte monoclonal antibodies in the diagnosis of Hodgkin's disease. 371 3
A phase II study of mitoxantrone (MIT) was performed in 13 cases of refractory malignant lymphoma, 1 of
Hodgkin's disease
and 12 of non-
Hodgkin lymphoma
. The twelve non-
Hodgkin
lymphomas were previously treated with adriamycin. MIT was diluted in 50 approximately 100 ml saline solution and intravenously administered by drip infusion in 15 approximately 30 minutes. The dose of MIT was 3 mg/m2/day for 5 days (A) or 10 approximately 14 mg/m2/day, for 1 day (B). There were 2 CR, 1 MR, 1 NC and 2 PD among 8 cases treated by schedule A, and two cases were not evaluable. With schedule B, there was 1 MR among 5 cases, and four cases were not evaluable. In the 7 evaluable cases, remission rate was 2/7 (29%) with remission durations of 6+ weeks and 55 weeks. The dose limiting toxicity was granulocytopenia but no serious infection was observed. With schedule A, it was difficult to repeat the treatment every 3 weeks because of the delay in
granulocyte
recovery. Gastrointestinal toxicities were observed in about half of the treatment courses but they were mild in degree. A prolongation of QTc (greater than 0.44) was observed in 3 cases (4 treatment courses) among 9 cases (10 treatment courses) whose baseline QTc values were within normal limits. Baseline QTc values were above the normal limit in 4 cases and in two of them, QTc showed further prolongation after MIT treatment. No arrhythmia or congestive heart failure was observed.
...
PMID:[A phase II study of mitoxantrone in malignant lymphoma]. 374 Aug 61
Tissue sections embedded in paraffin and fixed in formalin from 32 patients with
Hodgkin's disease
, representing the major histological subtypes, were studied using two
granulocyte
specific monoclonal antibodies (Leu-M1 and 3C4) and an HLA-D region specific monoclonal antibody (TAL-IB5). Reed-Sternberg cells were stained with one or other of the antigranulocyte antibodies in the nodular sclerosing and lymphocyte depleted subtypes. Reed-Sternberg cells in all but three cases of mixed cellularity
Hodgkin's disease
were positive with both Leu-M1 and 3C4. One case stained with only Leu-M1, and two cases were consistently negative with both antibodies. HLA-DR was widely expressed in the Reed-Sternberg cells of all three subtypes. In the four cases of lymphocyte predominant
Hodgkin's disease
the multinucleated Reed-Sternberg cells did not stain with either antigranulocyte antibody but were strongly positive with anti-HLA-DR. Twenty five cases of non-Hodgkin's lymphoma, in which there were multinucleated giant cells resembling Reed-Sternberg cells, were studied in a similar way. These cases included pleomorphic T cell and B cell lymphomas, histiocytic lymphomas, and malignant histiocytosis of the intestine. In none of these did the multinucleated cells stain with either antigranulocyte antibody, but in most cases the multinucleated cells stained with anti-HLA-DR. In two cases of the tumour stage of mycosis fungoides dot like intracytoplasmic staining was shown in the tumour cells with both antigranulocyte markers. The monoclonal antigranulocyte antibodies Leu-M1 and 3C4 are of considerable value in both the diagnosis and the differential diagnosis of
Hodgkin's disease
and are particularly valuable in that they can be applied to tissue fixed in formalin and embedded in paraffin. Antibody to HLA-DR, while useful, is of less value.
...
PMID:Granulocyte and HLA-D region specific monoclonal antibodies in the diagnosis of Hodgkin's disease. 386 94
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>